Clinical Study
Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
Table 4
Treatment outcomes Stage IIIA versus Stage IIIC epithelial ovarian cancer, University of Kentucky Markey Cancer Center 2000–2009.
| | | IIIA | IIIC | Significance | | | () | () |
| | Complete debulking (no visible residual disease) | 15 (100%) | 64 (34.4%) | | | Complete response to chemotherapy | 15 (100%) | 138 (74.2%) | | | Time to progression | | | | | Median (months) | 29 | 13 | | | Mean (months)* | | | | | Range (months) | 15–75 | 2–123 | | | Site of recurrence | | | | | Intraperitoneal | 7 (46.7%) | 137 (73.7%) | | | Intra- + extraperitoneal | 0 | 8 (4.3%) | | | Extraperitoneal | 0 | 14 (7.5%) | | | NED** | 8 (53.3%) | 27 (14.5%) | | | Overall survival | | | | | 2 years | 93.3% | 72.0% | | | 5 years | 60.0% | 41.8% | |
|
|
Mean ± standard error of mean.
NED: no evidence of disease.
|
